Confirm Rx insertable cardiac monitor for primary atrial fibrillation detection in high-risk heart failure patients (Confirm-AF trial)

Annals of noninvasive electrocardiology: the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc

article

Mehmet K. Aktas¹  Wojciech Zareba²  Javed Butler³  Arwa Younis²  Scott McNitt²  Mary W. Brown²  Nikhila Rao²  Nilesh Rao²  Jonathan Steinberg²  Leway Chen¹  Jeffrey D. Alexis¹  Himabindu Vidula¹  Ilan Goldenberg² 

[1] Division of Cardiology, University of Rochester Medical Center;Clinical Cardiovascular Research Center, University of Rochester Medical Center;Baylor Scott and White Research Institute;Department of Cardiology, University of Mississippi;Clinical Electrophysiology, Department of Cardiology, Cleveland Clinic;Summit Medical Group

关键词: atrial fibrillation;    heart failure;    implantable cardiac monitor;    remote monitoring;    stroke;   

DOI  :  10.1111/anec.13021

来源: Wiley

【 摘 要 】

BackgroundPatients with heart failure (HF) represent a large population of patients who are at high risk for complications related to undiagnosed atrial fibrillation (AF). However, currently there are limited modalities available for early AF detection in this high-risk population. An implantable cardiac monitor (ICM) is inserted subcutaneously and can provide long-term arrhythmia information via remote monitoring. Methods and Results 5 min using an Abbott ICM compared to non-ICM monitoring in symptomatic HF patients. This article describes the design and analytic plan for the Confirm-AF trial. Conclusions 35% using an Abbott ICM. A finding showing significantly higher incidence of AF along with improved clinical outcomes with ICM monitoring is expected to have substantial clinical implications and may change the method of monitoring high-risk HF patients.

【 授权许可】

Unknown